Item 5.07. Submission of Matters to a Vote of Security Holders.

At the Annual Meeting of Shareholders held on November 16, 2022 (the "Meeting"), the shareholders of Armata Pharmaceuticals, Inc. ("Armata") elected seven members to our board of directors, each for a one-year term expiring at the annual meeting of shareholders in 2023, as follows:





                                           Number of
                            Number of     Shares Voted
                           Shares Voted    Against or    Broker Non-
Members                        For         Abstained        Votes
Brian Varnum, Ph. D.        30,859,084      233,511        858,850
Jules Haimovitz             30,207,477      885,118        858,850
Odysseas D. Kostas, M.D.    30,227,120      865,475        858,850
Robin C. Kramer             30,968,830      123,765        858,850
Joseph M. Patti, Ph. D.     30,966,995      125,600        858,850
Todd C. Peterson, Ph. D.    30,966,799      125,796        858,850
Sarah Schlesinger, M.D.     30,862,657      229,938        858,850

At the Meeting, our shareholders next approved on a non-binding advisory basis, Armata's 2021 executive compensation. The vote for such approval was 31,049,313 shares for, 28,667 shares against, 14,615 shares abstaining, and 858,850 shares of broker non-votes.

Also at the Meeting, our shareholders ratified the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022. The vote for such ratification was 31,938,703 shares for, 6,798 shares against, 5,944 shares abstaining, and 0 shares of broker non-votes.

© Edgar Online, source Glimpses